Last reviewed · How we verify
DAPT
Dapt is a small molecule that works by interacting with specific biological targets, but the exact details of this interaction are unknown.
Dapt is a small molecule drug developed by Assistance Publique - Hôpitaux de Paris and currently owned by Baxter Healthcare Corp. However, due to the lack of information on its target, drug class, and approved indications, its exact mechanism and clinical use are unclear. As a small molecule, it is likely to work by interacting with specific biological targets, but the details of this interaction are unknown. Dapt is available as a generic medication, with 19 generic manufacturers, but its commercial status and safety considerations are not well-documented. Further research is needed to fully understand this medication.
At a glance
| Generic name | DAPT |
|---|---|
| Also known as | Active comparator, Dual antiplatelet therapy, Dual Anti Platelet Therapy, Ticagrelor or clopidogrel + aspirin, dual antiplatelet therapy |
| Sponsor | Baxter Hlthcare Corp |
| Target | Outer membrane porin protein OmpD |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Imagine your body's cells are like locks, and Dapt is a key that fits into those locks. When Dapt binds to its target, it can either block or enhance the activity of that target, depending on the specific lock it's interacting with. This can help to either reduce or increase the activity of certain cellular processes, but the exact way it works is still a mystery.
Approved indications
- Bacteremia caused by Staphylococcus aureus
- Complicated Skin and Skin Structure Enterococcus Faecalis Infection
- Complicated Skin and Skin Structure Staphylococcus Aureus Infection
- Complicated Skin and Skin Structure Streptococcus Agalactiae Infection
- Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
- Complicated Skin and Skin Structure Streptococcus dysgalactiae Infection
- Right-sided Staphylococcus aureus endocarditis
- Secondary infection of erosion and ulcer caused by MRSA
- Secondary infection of surgical wounds caused by MRSA
- Secondary infection of trauma, and burn wounds caused by MRSA
- Sepsis caused by methicillin resistant Staphylococcus aureus
- Sepsis due to Staphylococcus aureus
Common side effects
- Diarrhea
- Headache
- Dizziness
- Rash
- Abnormal liver function tests
- Elevated creatine phosphokinase (CPK)
- Urinary tract infections
- Hypotension
- Dyspnea
- Vomiting
- Abdominal pain
- Pruritus
Serious adverse events
- Anaphylaxis/Hypersensitivity Reactions
- Myopathy and Rhabdomyolysis
- Eosinophilic Pneumonia
- Drug Reaction with Eosinophilia and Systemic Symptoms
- Tubulointerstitial Nephritis
- Peripheral Neuropathy
- Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time
Key clinical trials
- Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent (PHASE4)
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia (PHASE4)
- The 10-Year Extended Follow-up of the DACAB Trial
- SIMPLAAFY Clinical Trial (NA)
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (PHASE3)
- Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention (PHASE4)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |